The U.S. Food and Drug Administration (FDA) has released results from what it calls the largest and most comprehensive testing of infant formula ever conducted in the U.S., offering new insight into chemical contaminants found in formula products sold nationwide. The testing is part of Operation Stork Speed, a broader federal effort to improve infant formula safety, nutrition, transparency, and supply chain resilience.
The results come as infant formula remains under intense public and legal scrutiny, particularly in lawsuits involving premature infants who developed necrotizing enterocolitis, or NEC, after allegedly receiving cow’s milk-based formula in neonatal intensive care units.
What Is Operation Stork Speed?
Operation Stork Speed was announced by the Department of Health and Human Services (HHS) and the FDA in March 2025 to expand access to safe, reliable, and nutritious infant formula. The initiative builds on oversight changes made after the 2022 formula shortage, when concerns about contaminated baby formula exposed weaknesses in manufacturing practices and the broader supply chain. It supports the FDA’s long-term strategy to strengthen the infant formula market.
The program includes several major priorities:
- A comprehensive review of infant formula nutrients
- Expanded testing for chemical contaminants
- Additional testing for microbiological contaminants
- Continued review of formula labeling and transparency
- Public updates about safety findings and nutrition standards
The FDA says the goal is not only to test products already on shelves but also to improve the monitoring of infant formula over time.
Key Findings From the FDA’s Infant Formula Testing
The FDA tested 312 infant formula samples from 16 brands, including powdered, concentrated liquid, and ready-to-feed products. The samples included cow’s milk-based, soy-based, and amino acid-based formulas. Testing looked for lead, mercury, cadmium, arsenic, PFAS, pesticides, phthalates, and other plasticizers.
According to the FDA, most samples had undetectable or very low levels of contaminants, and the agency said the results support the overall safety of the U.S. infant formula supply. However, the FDA also said some findings triggered follow-up testing and additional oversight.
The FDA emphasized that detecting a contaminant does not automatically mean a product is unsafe. Contaminants can appear in food because they occur naturally in the environment or enter the food supply through soil, water, air, ingredient sourcing, or manufacturing processes.
Why Infant Formula Oversight Matters for Parents
For many families, infant formula is essential. Some babies cannot breastfeed, some mothers cannot produce enough milk, and many premature infants require carefully managed nutrition in hospital settings.
That makes oversight especially important. Infants have smaller bodies and developing organ systems, which can make them more vulnerable to harmful exposures. The FDA’s Closer to Zero initiative focuses on reducing contaminants in foods for babies and young children to as low a level as possible while maintaining access to nutritious foods.
The latest testing does not mean every concern about infant formula has been resolved. Instead, it shows how federal regulators are trying to monitor risks more closely, identify areas for improvement, and hold manufacturers to evolving safety expectations.
How This Connects to NEC Infant Formula Lawsuits
The FDA’s contaminant testing is separate from the ongoing NEC infant formula lawsuits. Those lawsuits are not primarily about heavy metals, PFAS, or pesticides. Instead, they focus on allegations that cow’s milk-based formulas made for premature infants increased the risk of NEC and that manufacturers failed to warn hospitals and families about that risk.
NEC is a serious intestinal disease that primarily affects premature infants. Medical groups have long recognized human milk as important for premature infants, and the American Academy of Pediatrics recommends human milk for very low birth weight infants, preferably from the infant’s own mother when available.
Families pursuing NEC lawsuits allege that manufacturers knew or should have known about the increased NEC risk associated with cow’s milk-based products for premature infants. Manufacturers have denied those allegations and argue that their products are safe, medically necessary, and often critical when human milk is unavailable.
Recent NEC Verdicts Add Momentum to Ongoing Litigation
The legal debate over preterm infant formulas and NEC has intensified after recent jury verdicts. In April 2026, a Chicago jury ordered Abbott Laboratories to pay $70 million to four families who alleged the company failed to warn that its premature infant formula could cause NEC. Abbott said it plans to appeal and continues to dispute the claims.
These cases highlight a broader legal question: what information should hospitals, doctors, and parents receive when a product is used for highly vulnerable infants?
The central issue is often not whether a formula is ever necessary. In many NICU settings, it can be. The question is whether manufacturers provided clear, adequate warnings about known or knowable risks so medical providers and families could make informed decisions.
Why Transparency Remains Central to Safety and Legal Claims
Operation Stork Speed and NEC litigation involve different safety questions, but they share a common theme of transparency.
Parents rely on manufacturers, hospitals, doctors, and regulators to provide accurate information about infant nutrition. When a product is used for newborns, especially premature babies in intensive care, even small gaps in testing, labeling, communication, or warning practices can have serious consequences.
The FDA has said it will continue testing infant formula, including newer products entering the U.S. market, and will share follow-up results with the public. That continued oversight may help restore trust in the formula supply and give families more information about the products used to feed their children.
For families affected by NEC, however, the legal questions remain ongoing. As lawsuits move through state and federal courts, judges and juries will continue weighing what manufacturers knew, what they disclosed, and whether different warnings could have changed the decisions made in NICUs.
